# EDGAR Filing Document

**Accession Number:** 0002020932
**File Stem:** 0001104659-26-030833
**Filing Date:** 2026-3
**Character Count:** 8375
**Document Hash:** c39bd27bdc6cd80530f93b78016a36d1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-030833.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001104659-26-030833

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lefever Ellen
- **CENTRAL INDEX KEY:** 0002115887

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43098
- **FILM NUMBER:** 26768697

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O AGOMAB THERAPEUTICS NV
- **STREET 2:** POSTHOFLEI 1/6 2600
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Agomab Therapeutics NV
- **CENTRAL INDEX KEY:** 0002020932
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600
- **BUSINESS PHONE:** 32 3 302 35 30

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** POSTHOFLEI 1/6
- **CITY:** ANTWERPEN
- **PROVINCE COUNTRY:** C9
- **ZIP:** 2600

## Ex-24

**Exhibit 24**

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints the Chief Executive Officer and the Chief Financial Officer with full power to act as the undersigned's true and lawful attorneys-in-fact, with full power of substitution, to:

1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director and/or beneficial owner of AgomAb Therapeutics NV (the "Company"), the Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms 3, 4 and 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact or such attorney-in-fact's substitute or substitutes shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

This power of attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the attorney-in-fact.

**IN WITNESS WHEREOF**, the undersigned has caused this Power of Attorney to be executed as of this 13<sup>th</sup> day of February, 2026.

---

| | |
|:---|:---|
| By: | /s/ Ellen Lefever |
| Name: | Ellen Lefever |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lefever Ellen<br><sub>(Last) (First) (Middle)</sub><br>AGOMAB THERAPEUTICS NV<br>POSTHOFLEI 1/6<br><sub>(Street)</sub><br>ANTWERPEN, BELGIUM 2600<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Agomab Therapeutics NV [ AGMB ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_General Counsel_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2031-03-05 | Common shares<sup>(2)</sup> | 91256 | 2.76<sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2032-06-28 | Common shares<sup>(2)</sup> | 48009 | 2.76<sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2033-10-10 | Common shares<sup>(2)</sup> | 54113 | 2.76<sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2034-07-08 | Common shares<sup>(2)</sup> | 3832 | 2.76<sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2034-11-04 | Common shares<sup>(2)</sup> | 132122 | 3.18<sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2036-01-15 | Common shares<sup>(2)</sup> | 127972 | 14.26<sup>(3)</sup> | D |  |

---

### Footnotes:

(1) The shares underlying this option are fully vested and exercisable.

(2) The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

(3) The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

(4) 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

(5) 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Ellen Lefever  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**